Back to search

FORNY20-FORNY2020

Heart failure treatment solution

Alternative title: Heart failure treatment solution

Awarded: NOK 6.2 mill.

Project Number:

255191

Project Period:

2016 - 2016

Funding received from:

Organisation:

Location:

Severe heart failure patients today are often critically ill and only a small proportion qualifies for potentially lifesaving VAD (Ventricular Assist Device) treatment with currently available technologies. VAD pumps blood into the heart to help it function in order to sustain circulation to the vital organs. NUHEART AS were incorporated in 2014 by Vegard Tuseth to commercialize his game changing invention that offers considerable advantages over VADs used today. ?NUHEART? is an implantable, hyper-effective, miniature blood pump (VAD) with delivery kit including delivery system, pump with drivelines and power/steering unit without surgery for the treatment of severe heart failure patients demonstrating a hitherto unparalleled combination of efficacy, stability, versatility and safety. The novel design and deployment principles of NUHEART will permit use in existing patients but will also expand the patient population eligible for treatment. The concept is addressing a large unmet medical need within the critical heart failure patient population, Nueart?s potential impact includes saving lives, extending lives, improving quality of life and reducing health care costs. NUHEART overcomes the limitations of current technologies and of emerging technologies. In order to fulfil its potential, further technological and preclinical research into pump design and use (prototype development and assessment, preclinical research and testing, and human pilot studies) is required. This is the first product developed by NUHEART and the concept was designed by the company founder Vegard Tuseth MD, PhD. As a clinician and researcher, he has extensive exposure to existing therapies for the treatment of critical heart failure and understands well the current VAD technology and its limitations. Comprehensive international patents have been filed.

Funding scheme:

FORNY20-FORNY2020